Drug Trial Radar · NCT05684159
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 2027
Primary completion
Apr 2030
Study completion Feb 2031
Sponsor
- Lead sponsor
- NovelMed TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.
Conditions
- aHUS - Atypical Hemolytic Uremic Syndrome
Interventions
NM8074Drug
NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Normalization of platelet count (≥150 x 10^9/L)Time frame: Up to Study Day 120
- Normalization of LDH levels to below ULNTime frame: Up to Study Day 120
- Normalization of Schistocyte levels (<1%)Time frame: Up to Study Day 120
- Change from Baseline or Percent Change from Baseline in renal functionTime frame: Up to Study Day 120
- Change from Baseline or Percent Change from Baseline in HaptoglobinTime frame: Up to Study Day 120
- Change from Baseline or Percent Change from Baseline in HemoglobinTime frame: Up to Study Day 120
- Change from Baseline or Percent Change from Baseline in proteinuria/creatininuriaTime frame: Up to Study Day 120
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.